Vitamin D role and use in prediabetes

Endocrine Practice

Volumn 16, Issue 3, 2010, Pages 476-485

  Barengolts, Elena ^a  

^a JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ADIPOCYTOKINE; ALFACALCIDOL; CALCIDIOL 1 MONOOXYGENASE; CALCIFEDIOL; CALCITRIOL; CALCIUM; CALCIUM BINDING PROTEIN; CITRATE CALCIUM; COLECALCIFEROL; CYTOKINE; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PARATHYROID HORMONE; PHOSPHORUS; PLACEBO; PROINSULIN; VITAMIN D; VITAMIN D BINDING PROTEIN; 25-HYDROXYVITAMIN D; DRUG DERIVATIVE;

AFRICAN AMERICAN; BLOOD GLUCOSE MONITORING; CALCIUM METABOLISM; CHRONIC DISEASE; DIABETES MELLITUS; DIETARY INTAKE; ETHNIC DIFFERENCE; FOLLOW UP; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HISPANIC; HUMAN; HYPERGLYCEMIA; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTERVENTION STUDY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MEDLINE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SKIN COLOR; SUN EXPOSURE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; BLOOD; PATHOPHYSIOLOGY;

HUMANS; PREDIABETIC STATE; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 77956623539     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP09195.RA     Document Type: Review

References (80)

1. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med. 2009;169:626-632.
2. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the Unites States, 2007. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf. Accessed June 25, 2009.
3. Garber AJ, Handelsman Y, Einhorn D, et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia: When do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14:933-946.
4. Knekt P, Laaksonen M, Mattila C, et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology. 2008;19:666-671.
5. Forouhi NG, Luan J, Cooper A, Boucher JB, Wareham NJ. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: The Medical Research Council Ely Prospective Study 1990-2000. Diabetes. 2008;57:2619-2625.
6. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: An analysis of six prospective studies. Diabetes. 1997;46:701-710. (Pubitemid 27143390)
7. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168:1340-1349. (Pubitemid 351930842)
8. Ginde AA, Scragg R, Schwartz RS, Camargo CA Jr. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J Am Geriatr Soc. 2009;57:1595-1603.
9. Meigs, JB, Nathan, DM, D'Agostino RB Sr, Wilson PW; Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: The Framingham Offspring Study. Diabetes Care. 2002;25:1845-1850. (Pubitemid 41071098)
10. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. (Pubitemid 34437694)
11. Reimann M, Bonifacio E, Solimena M, et al. An update on preventive and regenerative therapies in diabetes mellitus. Pharmacol Ther. 2009;121:317-331.
12. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92:2017-2029. (Pubitemid 46997093)
13. Kotsa K, Yavropoulou MP, Anastasiou O, Yovos JG. Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertil Steril. 2009;92:1053-1058.
14. Nagpal J, Pande JN, Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med. 2009;26:19-27.
15. Tai K, Need AG, Horowitz M, Chapman IM. Glucose tolerance and vitamin D: Effects of treating vitamin D deficiency. Nutrition. 2008;24:950-956.
16. Liu E, Meigs JB, Pittas AG, et al. Plasma 25-hydroxyvitamin d is associated with markers of the insulin resistant phenotype in nondiabetic adults. J Nutr. 2009;139:329-334.
17. Peterson CA, Heffernan ME. Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J Inflamm (Lond). 2008;5:10.
18. Holick MF. Vitamin D: Importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004;79:362-371. (Pubitemid 41115577)
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
20. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency. A meta-analysis of randomized controlled trials. Arch Intern Med. 2009;169:551-561.
21. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr. 2007;85:1586-1591. (Pubitemid 46890428)
22. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80(Suppl 6):1689S-1696S
23. Hewison M, Burke F, Evans KN, et al. Extra-renal 25-hydroxyvitamin D3-1alpha-hydroxylase in human health and disease. J Steroid Biochem Mol Biol. 2007;103:316-321.
24. White P, Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab. 2000;11:320-327.
25. Rachez C, Freedman LP. Mechanisms of gene regulation by vitamin D(3) receptor: A network of coactivator interactions. Gene. 2000;246:9-21.
26. Ishida H, Norman AW. Demonstration of a high affinity receptor for 1,25-dihydroxyvitamin D3 in rat pancreas. Mol Cell Endocrinol. 1988;60:109-117. (Pubitemid 19005696)
27. Bland R, Markovic D, Hills CE, et al. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J Steroid Biochem Mol Biol. 2004;89-90:121-125. (Pubitemid 38844271)
28. Wooten MW, Nel AE, Goldschmidt-Clermont PJ, Galbraith RM, Wrenn RW. Identification of a major endogenous substrate for phospholipid/Ca2+-dependent kinase in pancreatic acini as Gc (vitamin D-binding protein). FEBS Lett. 1985;191:97-101. (Pubitemid 16234150)
29. Costa EM, Blau HM, Feldman D. 1,25-dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells. Endocrinology. 1986;119:2214-2220.
30. Kamei Y, Kawada T, Kazuki R, Ono T, Kato S, Sugimoto E. Vitamin D receptor gene expression is up-regulated by 1, 25-dihydroxyvitamin D3 in 3T3-L1 preadipocytes. Biochem Biophys Res Commun. 1993;193:948-955. (Pubitemid 23209686)
31. Han S, Chiang JY. Mechanism of vitamin D receptor inhibition of cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes. Drug Metab Dispos. 2009;37:469-478.
32. Zeitz U, Weber K, Soegiarto DW et al. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 2003;17:509-511.
33. Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology. 1986;119:84-90. (Pubitemid 16100711)
34. Chertow BS, Sivitz WI, Baranetsky NG, Clark SA, Waite A, Deluca HF. Cellular mechanisms of insulin release: The effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology. 1983;113:1511-1518. (Pubitemid 13009167)
35. Bourlon PM, Billaudel B, Faure-Dussert A. Influence of vitamin D3 deficiency and 1,25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J Endocrinol. 1999;160:87-95. (Pubitemid 29044571)
36. Maestro B, Dávila N, Carranza MC, Calle C. Identification of a vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol. 2003;84:223-230. (Pubitemid 36514839)
37. Maestro B, Campión J, Dávila N, Calle C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J. 2000;47:383-391.
38. Carlberg C, Dunlop TW, Saramäki A, Sinkkonen L, Matilainen M, Väisänen S. Controlling the chromatin organization of vitamin D target genes by multiple vitamin D receptor binding sites. J Steroid Biochem Mol Biol. 2007;103:338-343. (Pubitemid 46401335)
39. Sooy K, Schermerhorn T, Noda M, et al. Calbindin- D(28k) controls [Ca(2+)](i) and insulin release. Evidence obtained from calbindin-d(28k) knockout mice and betacell lines. J Biol Chem. 1999;274:34343-34349. (Pubitemid 129511777)
40. Rabinovitch A, Suarez-Pinzon WL, Sooy K, Strynadka K, Christakos S Expression of calbindin-D(28k) in a pancreatic islet beta-cell line protects against cytokine- induced apoptosis and necrosis. Endocrinology. 2001;142:3649-3655. (Pubitemid 32681776)
41. Riachy R, Vandewalle B, Kerr Conte J, et al. 1,25-Dihydroxyvitamin D3 protects RINm5F and human islet cells against cytokine-induced apoptosis: Implication of the antiapoptotic protein A20. Endocrinology. 2002;143:4809-4819.
42. Gysemans CA, Cardozo AK, Callewaert H, et al. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: Implications for prevention of diabetes in nonobese diabetic mice. Endocrinology. 2005;146:1956-1964.
43. Oh JY, Barrett-Connor E. Association between vitamin D receptor polymorphism and type 2 diabetes or metabolic syndrome in community-dwelling older adults: The Rancho Bernardo Study. Metabolism. 2002;51:356-359. (Pubitemid 34232638)
44. Ogunkolade BW, Boucher BJ, Prahl JM, et al. Vitamin D receptor (VDR) mRNA and VDR protein levels in relation to vitamin D status, insulin secretory capacity, and VDR genotype in Bangladeshi Asians. Diabetes. 2002;51:2294-2300. (Pubitemid 34729038)
45. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27:2813-2818. (Pubitemid 39565042)
46. Need AG, O'Loughlin PD, Horowitz M, Nordin BE. Relationship between fasting serum glucose, age, body mass index and serum 25 hydroxyvitamin D in postmenopausal women. Clin Endocrinol (Oxf). 2005;62:738-741. (Pubitemid 40825945)
47. Reis JP, von Mühlen D, Miller ER 3rd. Relation of 25-hydroxyvitamin D and parathyroid hormone levels with metabolic syndrome among US adults. Eur J Endocrinol. 2008;159:41-48. (Pubitemid 351969129)
48. Reis JP, von Mühlen D, Kritz-Silverstein D, Wingard DL, Barrett-Connor E. Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care. 2007;30:1549-1555. (Pubitemid 46871169)
49. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79:820-825. (Pubitemid 41103882)
50. Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract. 1995;27:181-188.
51. Baynes KC, Boucher BJ, Feskens EJ, Kromhout D. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia. 1997;40:344-347. (Pubitemid 27096561)
52. Hyppönen E, Boucher BJ, Berry DJ, Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: A cross-sectional study in the 1958 British Birth Cohort. Diabetes. 2008;57:298-305.
53. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care. 2005;28:1228-1230. (Pubitemid 40616645)
54. Wareham NJ, Byrne CD, Carr C, Day NE, Boucher BJ, Hales CN. Glucose intolerance is associated with altered calcium homeostasis: A possible link between increased serum calcium concentration and cardiovascular disease mortality. Metabolism. 1997;46:1171-1177. (Pubitemid 27418507)
55. Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care. 2005;28:2926-2932. (Pubitemid 43942926)
56. Pittas AG, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care. 2006;29:650-656. (Pubitemid 44115368)
57. Ashraf A, Alvarez J, Saenz K, Gower B, McCormick K, Franklin F. Threshold for effects of vitamin D deficiency on glucose metabolism in obese female African-American adolescents. J Clin Endocrinol Metab. 2009;94:3200-3206.
58. Arguelles LM, Langman CB, Ariza AJ, et al. Heritability and environmental factors affecting vitamin D status in rural Chinese adolescent twins. J Clin Endocrinol Metab. 2009;94:3273-3281.
59. Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJ. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia 1995;38:1239-1245.
60. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007;30:980-986. (Pubitemid 46556596)
61. von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br J Nutr. 2010;103:549-555.
62. Ljunghall S, Lind L, Lithell H, et al. Treatment with one-alpha-hydroxycholecalciferol in middle-aged men with impaired glucose tolerance--a prospective randomized double-blind study. Acta Med Scand. 1987;222:361-367. (Pubitemid 18049118)
63. Lind L, Pollare T, Hvarfner A, Lithell H, Sorensen OH, Ljunghall S. Long-term treatment with active vitamin D (alphacalcidol) in middle-aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure. Diabetes Res. 1989;11:141-147.
64. Nyomba BL, Auwerx J, Bormans V, et al. Pancreatic secretion in man with subclinical vitamin D deficiency. Diabetologia. 1986;29:34-38. (Pubitemid 16162739)
65. Borissova AM, Tankova T, Kirilov G, Dakovska L, Kovacheva R. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract. 2003;57:258-261. (Pubitemid 36700706)
66. Inomata S, Kadowaki S, Yamatani T, Fukase M, Fujita T. Effect of 1 alpha (OH)-vitamin D3 on insulin secretion in diabetes mellitus. Bone Miner. 1986;1:187-192. (Pubitemid 16015701)
67. Orwoll E, Riddle M, Prince M. Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am J Clin Nutr. 1994;59:1083-1087.
68. Jorde R, Figenschau Y. Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr. 2009;48:349-354.
69. Rudnicki PM, Mølsted-Pedersen L. Effect of 1,25- dihydroxycholecalciferol on glucose metabolism in gestational diabetes mellitus. Diabetologia. 1997;40:40-44. (Pubitemid 27035708)
70. Taylor AV, Wise PH. Vitamin D replacement in Asians with diabetes may increase insulin resistance. Postgrad Med J. 1998;74:365-366. (Pubitemid 28291246)
71. Fliser D, Stefanski A, Franek E, Fode P, Gudarzi A, Ritz E. No effect of calcitriol on insulin-mediated glucose uptake in healthy subjects. Eur J Clin Invest. 1997;27:629-633. (Pubitemid 27320041)
72. Gannage-Yared MH, Azoury M, Mansour I, Baddoura R, Halaby G, Naaman R. Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. J Endocrinol Invest. 2003;26:748-753. (Pubitemid 37451753)
73. Nilas L, Christiansen C. Treatment with vitamin D or its analogues does not change body weight or blood glucose level in postmenopausal women. Int J Obes. 1984;8:407-411. (Pubitemid 15215948)
74. Zofková I, Stolba P. Effect of calcitriol and trifluoperazine on glucose stimulated B cell function in healthy humans. Exp Clin Endocrinol. 1990;96:185-191.
75. Gedik O, Akalin S. Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. Diabetologia. 1986;29:142-145. (Pubitemid 16137021)
76. Timms PM, Mannan N, Hitman GA, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: Mechanisms for inflammatory damage in chronic disorders? QJM. 2002;95:787-796.
77. Cigolini M, Iagulli MP, Miconi V, Galiotto M, Lombardi S, Targher G. Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2006;29:722-724. (Pubitemid 44115386)
78. Standing Committee and the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academies Press, 1999: 71-145.
79. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;257: 266-281.
80. Cranney A, Horsley T, O'Donnell S, et al. Effectiveness and Safety of Vitamin D in Relation to Bone Health. Evidence Report/Technology Assessment No. 158 (Prepared by the University of Ottawa Evidence-based Practice Center (UO-EPC) under Contract No. 290-02-0021. AHRQ Publication No. 07-E013. Rockville, MD: Agency for Healthcare Research and Quality. 2007:185-204. www.ahrq.gov/clinic/tp/vitadtp.htm.